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CObjectives: Develop and validate a Spanish society of contraception
quality-of-life (SEC-QOL) questionnaire to assess the impact of contra-
ceptive methods on the health-related quality of life (HRQOL) of
women. Methods: SEC-QOL was developed following a standardized
procedure including review of the literature, interviews with contra-
ception users, and the administration of a pilot questionnaire to 187
women. SEC-QOL consists of 19 items and includes five dimensions. To
validate the questionnaire, a multicenter, observational, prospective
study was conducted in Spain. The following three study groups were
defined: group A (n  129) comprised women using effective contra-
ceptive methods; group B (n  251), comprised women about to start
using an effective method; and group C (n  73) comprised women
sing no or poorly effective contraception. All women attended base-
ine and final visits (4  1 months). Participants completed the SEC-
OL, psychological well-being index, EuroQol five-dimensional ques-
ionnaire, and perceived health state questionnaires. Results: At
aseline, women from group A had a better HRQOL in all SEC-QOL O
s and
al So
doi:10.1016/j.jval.2011.08.1729imensions, except for breast symptoms. Heavier menstrual bleeding,
ore androgenic and breast symptoms, menstrual pain, and not using
ormonal contraceptive methods were associated with lower HRQOL.
EC-QOL scores showed moderate correlations to psychological
ell-being index and slightly lower correlation to EuroQol five-di-
ensional questionnaire scores. At follow-up, HRQOL had improved
n all groups; most markedly in group B, which obtained an average
ffect size of 0.59. The minimum important difference was estab-
ished as a 3.4-point change in the global SEC-QOL score. SEC-QOL
btained a Cronbach’s  of 0.88 and an intraclass correlation coeffi-
ient of 0.82. Conclusions: SEC-QOL is a valid, reliable, and sensitive to
hange questionnaire for use in daily clinical practice and future re-
earch projects on contraception.
eywords: Contraception, Contraceptivemethods, Quality of life, Ques-
ionnaires, Validation.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The choice of a contraceptive method is mainly influenced by fac-
tors related to personal experience acquired from previously used
methods, including the degree of satisfactionwith themethod and
its influence on quality of life in general and sexuality in particular
[1–3]. Other elements involved include the effectiveness and ease
of use of themethod, its potential effects on skin, and its influence
on symptoms associated with the menstrual cycle [4,5] (fluid re-
tention, breast tension, abdominal swelling, excessive bleeding,
and catamenial headache). Effects associated with the menstrual
cycle have an influence on health-related quality of life (HRQOL),
particularly in women who use hormonal methods [6–8] that, be-
cause of their mechanism of action, significantly decrease most
symptoms related to the menstrual cycle (premenstrual symp-
toms, dysmenorrhea, and amount and duration of bleeding) [9].
To date, the few studies assessing the impact of use of the differ-
ent contraceptivemethods onHRQOLhaveused generic assessment
* Addess correspondence to: Luis Ignacio Lete, Department of Obstetric
E-mail: luisignacio.letelasa@osakidetza.net.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.tools [10], such as instruments specific to psychiatry (quality of life
enjoyment and satisfaction questionnaire) [8,11,12] or for directly as-
sessing the impact of menstrual cycle (Moos menstrual distress
questionnaire) [13]. None of these is a specific tool for assessing
HRQOL in women of childbearing age using contraceptive methods.
The objective of this project was to design and validate a question-
naire, the Spanish society of contraception quality-of-life (SEC-QOL)
questionnaire, which would allow for specifically assessing the im-
pact of contraceptive methods on the HRQOL of women and would
help health-care professionals in contraceptive counseling.
Methods
Questionnaire development
The SEC-QOL questionnaire was developed following a standard-
ized procedure. A comprehensive review of the scientific literature
was first conducted to identify the questionnaire contents with an
Gynecology, Hospital SantiagoApóstol, E-01004 Vitoria-Gasteiz. Spain.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
893V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 9 2 – 8 9 9expert group. In addition, 14 interviews were also conducted with
women of childbearing age (aged 18–48 years) from different geo-
graphic areas of Spain who were using hormonal and nonhor-
monal contraceptive methods. The most relevant statements ob-
tained from these interviews were used to prepare the
questionnaire, which was subsequently administered to another
group, this time consisting of 187 women. A preliminary analysis
of themeasurement properties of the questionnaire (internal con-
sistency and feasibility) and a Rasch analysis to reduce the num-
ber of items were performed using the responses collected [14].
The pilot test allowed the number of questionnaire items to be
reduced from 41 to 19 and gave a preliminary indication of the
good measurement properties of SEC-QOL.
The final self-administered questionnaire consists of 19 items
that allows for assessment of the following five dimensions: social
(5 items), menstrual symptoms (4 items), breast symptoms (3
items), psychological (4 items), and sexual (3 items) (Appendix
found in Supplemental Materials at 10.1016/j.jval.2011.08.1729).
Each item allows for five Likert-like response choices (from “al-
ways” to “never” or from “totally agree” to “totally disagree” de-
pending on the type of statement). Scores for the overall question-
naire and for each of its dimensions are obtained by adding the
responses to the corresponding items, with subsequent standard-
ization to a scale ranging from 0 (worst HRQOL) to 100 (best
HRQOL). Standardization is obtained as follows: (actual score –
minimum score)/(maximum score – minimum score)*100.
Questionnaire validation
To validate the questionnaire, a multicenter, observational, pro-
spective studywas conducted in Spain fromNovember 2008 to July
2009. Three study groups were defined based on the contraceptive
method used. The first group (“group A”) included women using
effective contraceptive methods such as hormonal contracep-
tives, consistent use of barrier contraceptives, intrauterine de-
vices, implants and injectables, male and female sterilization, and
dual methods (e.g., combination of a hormonal method plus a
barrier method). The main requirement was that this group of
women continued using suchmethods for the following 4months.
The second group (“group B”) includedwomenwhowere not using
any contraceptivemethod or were using a poorly effective contra-
ceptive method (chemical contraceptives, inconsistent condom
use, or natural methods) but who were to start using an effective
method from the study recruitment visit and who would use the
effective method for the following 4 months. Finally, the third
group (“group C”) comprised women who used no or poorly effec-
tive contraceptive methods and who, despite contraceptive coun-
seling by the physician, decided that they would continue to use a
poorly effective contraception or no contraception for the next 4
months. All women with diseases that could directly influence
their daily life, women who had received a hysterectomy, women
under study for infertility, women who had given birth within the
previous 6 months, women who were or wanted to become preg-
nant, and women participating in a clinical trial at the time of
study start were excluded from the study.
The women in Group B who did not continue with the contra-
ceptive method of their group at the time of their final visit were
reassigned to group C. In other words, the women in group B who
did not use an efficient contraceptive method at the time of their
second visit were analyzed as patients of group C. The women
included in the group A (effective contraceptive methods) who
changed or didn’t continue using an effective contraceptive
method, were eliminated from the analysis.
The study was approved by the ethics committee of Hospital
Universitario de Guadalajara (Spain).Sample size
The sample size required to assess themeasurement properties of
the SEC-QOL questionnaire was calculated for each study group.
Women in group Awere included to allow assessment of the test–
retest reliability of the questionnaire and were observed to obtain
an intraclass correlation coefficient of 0.7 or higher, assuming a
minimum ratio of 0.4. Assuming a significance level of 0.5, a sta-
tistical power of 0.80, and that 15% of patients would be lost to
follow-up or were not evaluable, a sample size of 126 women was
required.
Women in group B were included to allow assessment of sensi-
tivity to change of the SEC-QOL. The sample size was calculated to
detect changes in score of 0.2 standard deviations (small effect size
[15]) with a significance level of 0.05 and a statistical power of 0.80.
Assuming15%ofpatientswouldbe lost to follow-upornotevaluable,
the sample size calculated for this group was 231 women.
Finally, women in group C (or control group) were included to
allow detection of differences between the other two groups of
women using contraceptive methods (groups A and B) in SEC-QOL
scores. For this, a ratio of one control for every threewomen from the
other two groups was estimated. A sample size of 77 women was
required to detect differences of 0.4 standard deviations or higher
with a significance level of 0.05 and a statistical power of 0.80.
Study measurements
All women recruited into the study (Groups A, B, and C) attended
two visits, a baseline visit and a final visit at 4months (1month).
At the baseline visit, the following were recorded: sociodemo-
graphic data (age, place of birth, educational level, and employ-
ment status); reason for consultation (regular check-up, contra-
ceptive counseling, request for change in contraceptive method);
current contraceptive method used and method to be used from
that visit;menstrual interval (less than 21 days, 21 to 35 days,more
than 35 days, and other); bleeding intensity (heavy, normal,
scarce, or very scarce); presence or absence of pain related tomen-
ses (recorded using a 0–10 visual analog scale [VAS]); presence of
androgenic symptoms (acne, alopecia, oily skin, seborrheic der-
matitis, hirsutism); presence of premenstrual breast symptoms
(pain, increased sensitivity, enlargement, and breast discharge);
obstetric history by recording the obstetric formula; and personal
history of concomitant chronic diseases and life events (change of
partner or relationship status, occupational changes, changes in
family environment, housing and economic problems). At the fi-
nal visit, the same variables were recorded, except for sociodemo-
graphic characteristics, reason for consultation, and reason for
using contraceptives.
At both visits, study participants completed the specific SEC-
QOL questionnaire, the psychological well-being index (PWI) [16],
and the EuroQol five-dimensional (EQ-5D) questionnaire [17]; they
were asked about their perceived health state using a Likert scale
with five response options (from “very good” to “very poor”). All
questionnaires were given to participants for completion before
the interview with the physician.
Statistical method
A descriptive, comparative analysis of the sociodemographic and
clinical characteristics of group A, B, and C study participants was
performed. For group comparison, an analysis of variance
(ANOVA) test with the Bonferroni correctionwas used formultiple
comparisons of continuous variables, and a chi-square test was
used for categorical variables. Changes in clinical variables and
symptoms from baseline to the final visit were also compared in
the different study groups using the same statistical tests.
The feasibility of SEC-QOLwas assessed from the proportion of
missing responses for each item and the proportion of women
i894 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 9 2 – 8 9 9with valid responses to all questionnaire items. Mean time used to
complete the questionnaire was also analyzed in groups A and B.
Validity, reliability, and sensitivity to change were assessed as
measurement properties of SEC-QOL. Discriminant validity was
first assessed by comparing the questionnaire scores of the differ-
ent study groups, using an ANOVA test. In order to identify and
describe which variables were related to HRQOL, a bivariate anal-
ysis was first performed, followed by a linear regression, including
women from groups A and B and using as dependent variable the
global SEC-QOL score at the second visit (because this was the visit
for whichmore responses to the questionnaire fromwomen using
effective contraceptives were available). All sociodemographic
and clinical variables, negative vital events, and the contraceptive
method used were analyzed as independent variables.
To assess convergent validity, the relationship between the
scores in the SEC-QOL and scores obtained in the PWI and VAS of
the EQ-5D was analyzed using Pearson’s correlation coefficient.
Women fromgroupsA and Bwere included in this analysis. Scores
obtained in the questionnaire were analyzed based on the pres-
ence of problems in the items of the descriptive system of the
EQ-5D questionnaire using a Student’s t test.
To assess longitudinal validity, changes seen in scores in the
SEC-QOL questionnaire from the baseline to the final visit were
compared to the changes seen in clinical variables (menstrual in-
terval,menstrual pain, bleeding intensity, breast symptoms, num-
ber of symptoms, and adverse event occurrence) during the same
time period. For this, a Student’s t test, an ANOVA test, and the
Pearson’s correlation coefficient were used depending on the
type of variable analyzed. To assess sensitivity to change, the ef-
fect size (defined as the difference between themean baseline and
Table 1 – Sociodemographic characteristics of women recru
G
Age (years), mean (SD)* 29
Place of birth, N (%)
Spain 11
Eastern Europe
Latin America
North Africa
Other
Total 12
Educational level†, N (%)
No education
Primary education 1
Secondary education 5
University studies 6
Total 12
Marital status, N (%)
Married 4
Couple living together but not married 2
Stable relationship but not living together 4
No stable relationship
Separated/divorced
Widow
Unmarried couple
No answer
Total 12
Employment status, N (%)
Working 8
Unemployed 1
Student 2
Other
Total 12*P  0.001; †P  0.005.final scores, divided by the standard deviation obtained at base-
line) obtained in SEC-QOL was calculated. Theminimal important
difference of the questionnaire (defined as the smallest difference
in scores of a questionnaire perceived by the patient as beneficial)
was estimated as the difference seen by women who stated that
their health status had “slightly improved” at 4 months of study
start.
Finally, the internal consistency and test–retest reliability of
the specific questionnaire were assessed. Internal consistency
was calculated using a Cronbach’s  statistic for all women partic-
pating in the study [18] (for both the overall questionnaire and
dimension scores). Test–retest reliability was assessed in group A
women using intraclass correlation coefficient.
SPSS for Windows version 15.0 (SPSS, University of Chicago,
Chicago, IL) was used for statistical data analysis. A significance
level of 0.05 was considered for all group comparisons.
Results
Sample description
A total of 453 women were included. Of these, 129 (28.4%) used
effective methods and continued to use them after the baseline
visit (group A), 251 (55.4%) did not use effective contraceptive
methods and started to use them from the first study visit (group
B), and 73 (16.1%) did not use effective contraceptive methods and
did not use them throughout the study (group C). Table 1 provides
the sociodemographic characteristics of study participants.
Women in group C had a slightly higher mean age (33.6 years old)
into the study.
A Group B Group C
) 28 (7.4) 33.6 (9.1)
.1%) 207 (82.5%) 63 (86.3%)
%) 7 (2.8%) 6 (8.2%)
%) 34 (13.5%) 4 (5.5%)
%) 2 (0.8%) 0
%) 1 (0.4%) 0
0%) 251 (100%) 73 (100%)
1 (0.4%) 1 (1.4%)
.1%) 58 (23.1%) 14 (19.4%)
.3%) 109 (43.4%) 31 (43.1%)
.6%) 83 (33.1%) 26 (36.1%)
0%) 251 (100%) 72 (100%)
.3%) 85 (34.0%) 34 (47.2%)
.9%) 46 (18.4%) 11 (15.3%)
.0%) 95 (38.0%) 12 (16.7%)
%) 16 (6.4%) 9 (12.5%)
%) 4 (1.6%) 5 (6.9%)
1 (0.4%) 0
%) 1 (0.4%) 1 (1.4%)
%) 2 (0.8%) 0
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895V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 9 2 – 8 9 9thanwomen in the two other groups (29.3 years old in group A and
28.0 years old in group B) (P  0.001). Statistically significant dif-
erences were also seen in educational level; 89.9% of women in
roup A stated that they had secondary or university education,
ompared with 76.5% and 79.2% in groups B and C, respectively
P  0.005). There were no differences in marital or occupational
tatus.
In the final visit, two of the participants in group A did not
ccomplish the conditions of their group; i.e., they used inefficient
ontraceptive methods instead of using efficient contraceptive
ethods. For this reason those women were excluded from the
nalysis population. Final analysis of group A revealed that 127
omen completed visit 1 and 108 women completed visit 2. Of the
51 women in group B, 197 completed the second visit. Of those
97, 10 did not change their contraception methods (they did not
ccomplish the inclusion criteria of group B). Those women ac-
omplished the inclusion criteria of group C, and finally those
omen were included in this group. Therefore, for group B we
onsidered 241 women in visit 1 and 187 women in visit 2. This
eans that, for group C, 83 women were considered for the basal
isit (73 10) and 8 of them did not complete the second visit (75
omen on visit 2).
The main reason for consultation was a regular health
check-up in 78.7% and 77.1% of women in groups A and C, respec-
tively, whereas the most common reason (56.4%) in group B was
contraceptive counseling. Among women who did not use any
effective contraceptive method at baseline (women from groups B
and C), the most common method was inconsistent condom use
(78.8% and 62.7%, respectively), followed by coitus interruptus
(18.7% and 24.1%). Amongwomenusing an effective contraceptive
method at the baseline visit (group A), 42.5% stated that they used
the contraceptive pill and 24.4% used condoms consistently (Table
2). With respect to the mean (SD) number of years women had
been using the same contraceptive method, the longest period
was found for group C women (6.4 [6.9], compared with 4.0 [3.9]
and 3.8 [4.5] for women from groups A and B, respectively; P 
.001). Of women from group B who switched from a poorly effec-
ive to an effective contraceptive method, 38.6% were planning to
hange to the contraceptive pill. Besides contraception, regulation
f themenstrual cycle was reported as another reason for starting
ontraceptive use by 23.6% of group A women and by 12.0% of
roup B women.
At the baseline visit,more than 84% ofwomen in all groups had
ormal menstrual cycles (menstrual interval ranging from 21 and
5 days), with no significant differences between the different
tudy groups. By contrast, statistically significant differenceswere
ound in bleeding intensity, which was greater among women
Table 2 – Contraceptive methods used at the baseline visit
Group B
n (%)
Gr
None 23 (9.5%) 14
Spermicide 0 1
Ovules 1 (0.4%)
Creams 0 1
Gels 0
Inconsistent condom 190 (78.8%) 52
Coitus interruptus 45 (18.7%) 20
Ogino 4 (1.7%) 2
Temperature 0 1
Symptothermal 0 1
Total 241 (100%) 83IUD, intrauterine device.rom groups B and C than those from group A (P  0.001). For this
ame variable, a statistically significant decrease was seen from
he baseline to the final visit in group B women only (P  0.001).
ith respect to menstrual pain, group A women had less pain
han those from the two other groups (P  0.001). However, a sta-
istically significant decrease from the baseline to the final visit
as only seen in group B women (P  0.001). The most common
ndrogenic symptomswere acne, oily skin, and greasy hair, but no
tatistically significant differences were seen between the groups.
he number of androgenic symptoms decreased in group B
omen from the baseline to the final visit (P  0.001). With regard
o breast symptoms, themost commonwas an increased premen-
trual breast tenderness, occurring in 44.4%of groupAwomenand
n 56.5% and 67.5% of women from groups B and C, respectively.
ifferenceswere seen between the groups in the number of breast
ymptoms.Women fromgroup Bwere the only oneswho reported
statistically significant decrease in the number of breast symp-
oms from the baseline to the final visit (P  0.002).
Validation of SEC-QOL
Feasibility
A total of 96.4% women answered 100% of the items of SEC-QOL.
The missing response rate was less than 2% in all questionnaire
items. Mean administration time was 6.1 minutes.
Validation
Figure 1 shows the baseline scores obtained in the SEC-QOL ques-
tionnaire by the different study groups. Statistically significant
differences were seen between group A women (using effective
contraceptive methods) and women from groups B and C (not us-
ing effective contraceptive methods until the time of visit) in all
dimensions (P  0.05), except for breast symptoms. Women from
group A had a better HRQOL. Statistical significant differences in
HRQOL between study groups were confirmed (P  0.01) using a
egression model adjusting by age and marital status.
When variables related to HRQOL were assessed by jointly an-
lyzing women from groups A and B, a relationship was seen with
enstrual bleeding and pain, but not with duration of menstrual
nterval. Women with a greater menstrual bleeding intensity also
evealed reduced HRQOL according to the global SEC-QOL score
P  0.01) as well as the scores for the menstrual symptom (P 
0.05) and psychological (p0.01) dimensions. Women with more
severemenstrual pain also indicated reduced HRQOL according to
all SEC-QOL scores (global and by dimensions) (P  0.02 for the
sexual dimension and P  0.01 for all other scores).
tudy group.
C Group A
n (%)
%) Pill 54 (42.5%)
) Gestagen-only pill 1 (0.8%)
Patch 1 (0.8%)
) Ring 16 (12.6%)
Implant 1 (0.8%)
%) Levonorgestrel IUD 12 (9.4%)
%) Injectable 1 (0.8%)
) Condom 31 (24.4%)
) IUD 6 (4.7%)
) Vasectomy 3 (2.4%)
) Hormonal  condom 3 (2.4%)
Total 127 (100%)by s
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by study participants was found to have an impact on HRQOL. The
number of breast symptoms experienced indicated a Pearson’s
correlation coefficient of 0.64 (P  0.01) with the breast symptom
dimension and a coefficient ranging from 0.13 to 0.37 (P  0.05)
with all other dimensions, except for the sexual dimension, which
had a very low Pearson’s correlation coefficient of 0.01 (P  0.94).
he number of androgenic symptoms demonstrated a statistically
ignificant but small (0.133) Pearson’s correlation coefficient with
he global SEC-QOL score.
A bivariate analysis revealed that womenwith a poorer HRQOL
ncluded those with greater menstrual bleeding intensity, more
ndrogenic and breast symptoms, menstrual pain, and patients
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Fig. 1 – Mean baseline total and
Table 3 – Coefficients obtained in the bivariate and multiva
global SEC-QOL score.
Bivar
Independent variables at final visit Beta
Breast symptoms 0.300
Menstrual pain 0.375
Use hormonal method 0.186
Bleeding intensity 0.188
Androgenic symptoms 0.132
Use levonor. IUD 0.150
Use condoms 0.148
Use IUD 0.121
Use pill 0.083
Use ring 0.048
Use patch 0.111
Age 0.098
Menstrual interval 0.001
Some bad event 0.091IUD, intrauterine device.ho did not use hormonal contraceptive methods. Subsequently,
n the multivariate regression model, the variables found to be
ignificant included breast symptoms (the greater their presence,
he lower HRQOL), menstrual pain intensity (the greater the pain,
he poorer HRQOL), and use of hormonal methods (better HRQOL
mong users of these methods) (Table 3).
SEC-QOL scores indicated moderate correlations to PWI
cores. The highest correlation coefficients were found in the
sychological dimension of SEC-QOL, followed by global score.
he social and menstrual symptom dimensions of the SEC-QOL
ad a greater correlation to the vitality and general health di-
ensions of PWI than to all other questionnaire dimensions
Table 4). The correlations observed in the EQ-5D VAS are
55.0
72.2
53.8
47.7
60.1
38.8
43.9
60.0
42.9
Breast
Symptoms
Psychological
D.
Sexual D.
Group C
A vs B†
A vs C†
A vs B†
A vs C*A vs C*
ension scores by study group.
regression models to analyze variables related to the
egressions Multivariate model
P value Beta P value
0.001 0.210 0.001
0.001 0.297 0.001
0.001 0.130 0.035
0.001 0.032 0.614
0.031 0.077 0.185
0.011
0.012
0.040
0.159
0.414
0.060
0.097
0.984
0.1210
54.9
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global SEC-QOL score. When SEC-QOL scores were analyzed ac-
cording to the level of problems in each of the EQ-5D dimen-
sions, the greatest differences were seen in relation to pain/
discomfort, anxiety/depression, and daily activities (Table 4).
The relationship between the question about the perceived
health state and SEC-QOL was statistically significant for all
dimensions (P  0.01) except for the sexual dimension.
As presented in Figure 2, HRQOL tended to improve in all
tudy groups from the baseline to the final visit, but this im-
rovement was more marked in women from group B. Only
roup A women had statistically significant improvements in
Table 4 – Correlations between SEC-QOL scores and the PW
Global score Social
dimensio
PWI (Pearson’s r)
Total 0.404* 0.350*
Anxiety 0.347* 0.273*
Depression 0.283* 0.256*
Positive mood 0.270* 0.253*
Vitality 0.412* 0.387*
Self-control 0.278* 0.224*
General health 0.405* 0.359*
EQ-5D VAS (Pearson’s r)
VAS 0.239* 0.224*
EQ-5D descriptive system (P value)
Mobility 0.169 0.633
Self-care 0.153 0.370
Daily activities 0.01 0.05
Pain/discomfort 0.01 0.01
Anxiety/depression 0.01 0.01
Health state (P value)
Health state (0–10) 0.01 0.01
EQ-5D, EuroQol questionnaire; PWI, psychological well-being index;
VAS, visual analogue scale.
*P  0.01; †P  0.05.
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Fig. 2 – Changes in scores obtained in each of the dimension
*P < 0.05; †P < 0.01.the overall SEC-QOL score (P  0.05) and in the psychological
dimension (P  0.01), whereas group B women had improve-
ments in global score (P  0.01) as well as the social (P  0.01),
psychological (P  0.01), and sexual (P  0.01) dimensions.
Group B women had a HRQOL similar to group C women at
baseline, but at the final visit their HRQOL was more similar to
that of group A women (P  0.01).
Sensitivity to change
The effect size (ES) obtained for all SEC-QOL scores were greater in
group Bwomen (0.14 to 0.59) compared with those in group A (0.06
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898 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 9 2 – 8 9 9to 0.24). In the overall score, group Bwomen obtained an ES of 0.59
(large ES), compared with an ES of 0.22 for group A women (small
ES) (Table 5).
The minimum important difference in this study was estab-
lished as a 3.4-point change in the global SEC-QOL score.Minimum
important difference is defined as the mean change in question-
naire scores perceived by patients as an improvement in HRQOL.
Reliability
The SEC-QOL questionnaire demonstrated a good internal consis-
tency, with an overall Cronbach’s  of 0.88 and a value higher than
.70 in all dimensions, except for the sexual dimension (0.55). The
verall intraclass correlation coefficient was 0.82, and was higher
han 0.70 in all dimensions, thus indicating the good test–retest
eliability of the questionnaire.
Discussion
Our results show the high feasibility, validity, sensitivity to
change, and reliability of the SEC-QOL as a specific questionnaire
to assess HRQOL in women of childbearing age who are using
contraceptive methods. The SEC-QOL consists of only 19 items
and may be administered in a short time. It is thus considered to
be suitable for use in standard clinical practice.
Various studies on HRQOL and contraception have demon-
strated that symptoms related to the menstrual cycle (fluid reten-
tion, breast tension, abdominal swelling, skin changes, heavy
bleeding, or migraine associated to menstrual cycle), as well as
symptoms such as depression, irritability, or mood changes are
related to a poorer HRQOL [6,19,20], which especially affects the
physical dimension and mood in women. The impact of premen-
strual symptoms on the daily life of women will depend on sever-
ity of such symptoms [21]. Because of the high prevalence of those
symptoms in women of childbearing age (estimated to represent
more than 70% in the United States [22]), it is important to individ-
ually assess not only the number of symptoms, but the impact of
regular occurrence of these symptoms on the life of women. The
results achieved using the SEC-QOL questionnaire, developed us-
ing a methodology taking into account, in addition to published
studies and expert opinions, the opinion ofwomen of childbearing
age using and not using contraceptive methods, reveal that previ-
ous or ongoing premenstrual symptoms have the greatest impact
on the daily life of women. By contrast, aspects related to the
efficacy of contraceptive methods do not appear to have a very
significant impact on HRQOL because the questionnaire only in-
cludes one question directly related to this aspect.
With regard to premenstrual symptoms, this study found that
premenstrual breast tension and intensity of menstrual bleeding
are symptoms with a great impact on the life of women who ex-
perience them. Women already using some effective contracep-
tive method at the baseline visit (group A) had better scores in the
menstrual and breast symptom dimensions than women who
were to start an effective contraceptive method (group B). In addi-
tion, women who start a hormonal contraceptive method have
also been shown to experience a significant improvement in
symptoms related to the menstrual cycle during the study, an
improvement also reflected in an increase in SEC-QOL scores. The
relationship found between a greater bleeding intensity, a greater
number of androgenic and breast symptoms, a higher severity of
menstrual pain, and the use of nonhormonal contraceptive meth-
ods and a poorer quality of life agree with other studies relating
use of hormonal contraceptives to a decrease in premenstrual
symptoms [3,23,24].
A study intended to assess the impact of oral contraceptive
methods on quality of life (as assessed by the World Health Orga-
nization quality of life [WHOQOL]) in a Japanese population con-T G G G G G G S
899V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 8 9 2 – 8 9 9cluded that premenstrual symptoms had a great impact on the
social, physical, and psychological dimensions [11]. These results
also agreewith those seen in the SEC-QOL, suggesting that group B
women (with more premenstrual symptoms) have a greater im-
pairment in the psychological and social dimensions than group A
women (with less premenstrual symptoms). However, unlike ge-
neric questionnaires, the SEC-QOL includes specific dimensions
related to premenstrual (breast) and menstrual symptoms that
provide more specific information than the generic HRQOL ques-
tionnaires used to date, including the WHOQOL or short form 36
health survey. Results of this study indicate that the HRQOL of
women of childbearing age who use contraception methods is
highly related to severity of premenstrual symptoms and that the
choice of hormonal contraceptive methods is highly focused on
the minimization of such symptoms; not just obtaining the con-
traceptive effect.
Although no changewasmade in the category of contraceptive
method used by group A women during the study follow-up pe-
riod, these women indicated a slight improvement in HRQOL.
Such improvement may have been due, first of all, to the partici-
pation of women in this study, which resulted in closer medical
monitoring of women (more visits and longer duration of visits)
and an assessment by the physician of more relevant aspects per-
ceptible by patients, such as HRQOL. Second, the fact that about
12% of group A women changed from using condom to hormonal
contraceptive methods may have an impact on HRQOL.
Themain limitation of this study is the follow-up period,which
lasted 4 months, previous contraception studies defined a fol-
low-up period between 3 and 6 months. Although 4 months may
not appear long enough to assess changes in HRQOL score, partic-
ularly those related to premenstrual symptoms in group Bwomen,
this limitation is minimized by the finding of a high sensitivity to
change (large ES) of the SEC-QOL in this group of women, which
means that the questionnaire is able to detect even small changes
in the health state of women.
In conclusion, this study permitted the evaluation of the mea-
surement properties of the first HRQOL questionnaire specific for
women of childbearing age who are using contraceptive methods.
The results achieved suggest that the SEC-QOL is valid for use both
in daily clinical practice and in future research projects to assess
HRQOL of women on contraception. Finally, this study also dem-
onstrated the significance and impact of premenstrual symptoms
on HRQOL experienced by women of childbearing age.
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